Up to 1,600 patients are expected to be enrolled in this study across Europe. The clinical trial will be opened in 80 sites in the following 8 countries within the EORTC network (Belgium, Croatia, Czechia, Denmark, Italy, Portugal, Romania, Slovenia) and 30 sites across national networks in Ireland, France, and Spain.4
The study is designed with a strong focus on patient centricity, employing a patient-developed health questionnaire to better assess quality of life improvements.
DE-ESCALATE is managed by a multidisciplinary and multistakeholder consortium involving clinical oncologists, surgeons, health economists, and patient representatives.
The DE-ESCALATE study may lead to improved patient survival and quality of life while also improve health system sustainability.
Read more about the DE-ESCALATE Trial and other EORTC Projects here: https://www.eortc.org/blog/2025/06/10/de-escalate-first-site-activated/
